CG Oncology Shares Rise Following Positive Phase 3 Trial Results for Bladder Cancer Immunotherapy
CG Oncology (CGON) shares increased approximately 9% during Monday morning trading following the announcement of successful phase 3 data. The PIVOT-006 trial evaluated cretostimogene grenadenorepvec, an adjuvant intravesical immunotherapy designed for patients with non-muscle invasive bladder cancer (NMIBC). The clinical trial met its primary endpoint, demonstrating a statistically significant reduction in the risk of recurrence compared to the control group. This development marks a potential milestone for the company's pipeline and its approach to treating NMIBC.

Tickers: $CGON
Topics: Immunotherapy NMIBC Phase 3 clinical trial Stock price movement
Read the full article at Seeking Alpha
Part of the story Biotech Sector Experiences Mixed Clinical and Regulatory Results (3 articles)